[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100432546":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":59,"locations":69,"responsibleParty":199,"collaborators":202,"id":206,"slug":207,"hasResults":208,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":208,"sex":214,"minAge":215,"maxAge":216,"enrollmentInfo":217,"targetDuration":25,"studyType":220,"phases":221,"briefSummary":223,"conditions":224,"keywords":228,"overallStatus":71,"whyStopped":25,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":240},{"fullName":5,"class":6},"Harbin Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dexmedetomidine (DEX) group","ACTIVE_COMPARATOR","The patient began to inject DEX intravenously as soon as he enrolled. This study started with the maximum maintenance dose allowed by the label (0.7μg\u002Fkg\u002Fh). With reference to previous studies, we set 3 pump injection gradients within the range of 0.2-0.7μg\u002Fkg\u002Fh (0.2μg\u002Fkg\u002Fh, 0.45μg\u002Fkg\u002Fh, 0.7μg\u002Fkg\u002Fh), and based on the patient's heart rate , systolic blood pressure and RASS sedation score to adjust.",[13],"Drug: Dexmedetomidine (DEX)",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo (Saline) group","PLACEBO_COMPARATOR","The patient began intravenous injection of normal saline immediately after enrollment. The administration method and dosage adjustment of normal saline are the same as DEX group.",[19],"Drug: Placebo (Saline)",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","Dexmedetomidine (DEX)",[9],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Placebo (Saline)","The patient began intravenous injection of normal saline immediately after enrollment. The administration method and dosage adjustment of normal saline are the same as DEX.",[15],[31,35,38,41,44,47,50,53,56],{"name":32,"affiliation":33,"role":34},"Bo Yu, M.D., FACC","The Second Affiliated Hospital of Harbin Medical University","PRINCIPAL_INVESTIGATOR",{"name":36,"affiliation":37,"role":34},"Xi Su","Wuhan Asia Heart Hospital",{"name":39,"affiliation":40,"role":34},"Xiaohui Zheng","Henan Provincial People's Hospital",{"name":42,"affiliation":43,"role":34},"Kai Liu","Mudanjiang cardiovascular hospital",{"name":45,"affiliation":46,"role":34},"Jian An","Shanxi Cardiovascular Hospital",{"name":48,"affiliation":49,"role":34},"Xiling Shou","Shaanxi Provincial People's Hospital",{"name":51,"affiliation":52,"role":34},"Chengzhi Lu","Tianjin First Central Hospital",{"name":54,"affiliation":55,"role":34},"Xianhe Lin","The First Affiliated Hospital of Anhui Medical University",{"name":57,"affiliation":58,"role":34},"Zheng Zhang","LanZhou University",[60,65],{"name":61,"role":62,"phone":63,"phoneExt":25,"email":64},"Jiannan Dai, M.D., Ph.D","CONTACT","+86 15124559838","daijiannandr@163.com",{"name":66,"role":62,"phone":67,"phoneExt":25,"email":68},"Jinfeng Tan, M.D.","+86 13633643383","418904005@qq.com",[70,88,103,116,130,143,157,171,185],{"facility":55,"status":71,"city":72,"state":73,"zip":74,"country":75,"countryCode":76,"cosmosGeoPoint":77,"geoPoint":82,"contacts":83},"RECRUITING","Hefei","Anhui","230000","China","CN",{"type":78,"coordinates":79},"Point",[80,81],117.28083,31.86389,{"lat":81,"lon":80},[84],{"name":85,"role":62,"phone":86,"phoneExt":25,"email":87},"Yangjing Xie","13721053618","xieyj2011@foxmail.com",{"facility":89,"status":71,"city":90,"state":91,"zip":92,"country":75,"countryCode":76,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"The First Affiliated Hospital of Lanzhou University","Lanzhou","Gansu","730000",{"type":78,"coordinates":94},[95,96],103.83987,36.05701,{"lat":96,"lon":95},[99],{"name":100,"role":62,"phone":101,"phoneExt":25,"email":102},"Bo Zhang","13359401106","783846183@qq.com",{"facility":33,"status":71,"city":104,"state":105,"zip":106,"country":75,"countryCode":76,"cosmosGeoPoint":107,"geoPoint":111,"contacts":112},"Harbin","Heilongjiang","150000",{"type":78,"coordinates":108},[109,110],126.65,45.75,{"lat":110,"lon":109},[113],{"name":114,"role":62,"phone":115,"phoneExt":25,"email":64},"Jiannan Dai","15124559838",{"facility":117,"status":71,"city":118,"state":105,"zip":119,"country":75,"countryCode":76,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"Mudanjiang Cardiovascular Hospital","Mudanjiang","1570011",{"type":78,"coordinates":121},[122,123],129.62594,44.54804,{"lat":123,"lon":122},[126],{"name":127,"role":62,"phone":128,"phoneExt":25,"email":129},"Wanqing Zhao","18946326812","xingyunxing158@yeah.net",{"facility":40,"status":71,"city":131,"state":132,"zip":133,"country":75,"countryCode":76,"cosmosGeoPoint":134,"geoPoint":138,"contacts":139},"Zhengzhou","Henan","450000",{"type":78,"coordinates":135},[136,137],113.64861,34.75778,{"lat":137,"lon":136},[140],{"name":39,"role":62,"phone":141,"phoneExt":25,"email":142},"18838910817","16859755@qq.com",{"facility":37,"status":71,"city":144,"state":145,"zip":146,"country":75,"countryCode":76,"cosmosGeoPoint":147,"geoPoint":151,"contacts":152},"Wuhan","Hubei","430022",{"type":78,"coordinates":148},[149,150],114.26667,30.58333,{"lat":150,"lon":149},[153],{"name":154,"role":62,"phone":155,"phoneExt":25,"email":156},"Sheng Bi","13971668450","bisheng_123123@163.com",{"facility":49,"status":71,"city":158,"state":159,"zip":160,"country":75,"countryCode":76,"cosmosGeoPoint":161,"geoPoint":165,"contacts":166},"Xi'an","Shaanxi","710068",{"type":78,"coordinates":162},[163,164],108.92861,34.25833,{"lat":164,"lon":163},[167],{"name":168,"role":62,"phone":169,"phoneExt":25,"email":170},"Nier Zhong","13201790519","zhongnier@sina.com",{"facility":46,"status":71,"city":172,"state":173,"zip":174,"country":75,"countryCode":76,"cosmosGeoPoint":175,"geoPoint":179,"contacts":180},"Taiyuan","Shanxi","30001",{"type":78,"coordinates":176},[177,178],112.56028,37.86944,{"lat":178,"lon":177},[181],{"name":182,"role":62,"phone":183,"phoneExt":25,"email":184},"Jingyi Liu","18235123471","Janeyiliu@163.com",{"facility":52,"status":71,"city":186,"state":187,"zip":188,"country":75,"countryCode":76,"cosmosGeoPoint":189,"geoPoint":193,"contacts":194},"Tianjin","Tianjin Municipality","300192",{"type":78,"coordinates":190},[191,192],117.17667,39.14222,{"lat":192,"lon":191},[195],{"name":196,"role":62,"phone":197,"phoneExt":25,"email":198},"Dachuan Xia","13902061361","xiadachuan@126.com",{"type":34,"investigatorFullName":200,"investigatorTitle":201,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Yu Bo","Director",[203],{"name":204,"class":205},"Yangtze River Pharmaceutical Group Co., Ltd.","INDUSTRY","100432546","cardioprotective-effect-of-dexmedetomidine-in-patients-with-st-segment-elevation-myocardial-infarction-100432546",false,"NCT04912518","Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction","Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction: a Double-Blind, Multicenter, Randomized, Placebo-Controlled Clinical Trial","COOPERATION","Inclusion Criteria: the enrolled subjects must meet all of the following criteria:\n\n* Aged 18-75 years old (inclusive);\n* Diagnosed with anterior STEMI within 6h of symptom onset: (1) ischemic chest discomfort; (2) electrocardiogram (ECG) with ST elevation ≥0.2 mV in 2 or more contiguous precordial leads (one of which should be V2, V3, or V4);\n* Sign the informed consent form.\n\nExclusion Criteria: subjects who meet any one of the following criteria are excluded from the study:\n\n* Ventricular fibrillation, cardiogenic shock, Killip III-IV grade;\n* Sinus bradycardia (heart rate sustained \\\u003C60 beats\u002Fmin), PR interval\\> 240ms or II-III degree atrioventricular block;\n* Continuous systolic blood pressure \\\u003C120mmHg;\n* Severe breathing difficulties, aterial blood oxygen saturation \\\u003C92%;\n* Thrombolytic therapy has been performed before the first medical contact in the hospital;\n* Consciousness disorder or past cerebrovascular disease;\n* Previous history of myocardial infarction or PCI\u002FCABG treatment;\n* Known severe liver and kidney dysfunction;\n* Known allergy to dexmedetomidine;\n* CMR contraindications: such as claustrophobia, pacemaker or ICD implantation;\n* Pregnant or lactating women;\n* Malignant tumor or expected survival time \\\u003C1 year;\n* Any condition which in the opinion of the investigator would make it unsafe or unsuitable for the patient to participate in this study (eg, poor compliance, inability of the patient to comply with study procedures and\u002For follow up);\n* Participate in other randomized controlled studies at the same time.","ALL","18 Years","75 Years",{"count":218,"type":219},250,"ESTIMATED","INTERVENTIONAL",[222],"NA","This is a double-blind, multicenter, randomized, placebo-controlled clinical trial. It is planned to enroll patients admitted with anterior ST-segment elevation myocardial infarction (STEMI) within 6h of symptom onset and undergo primary percutaneous coronary intervention (pPCI). Patients who meet the inclusion criteria and without exclusion criteria were randomized 1:1 into the dexmedetomidine (DEX) group or the placebo (saline) group after signing the informed consent. In the DEX group, intravenous injection of DEX was started immediately after enrollment, covering the entire PCI operation, and the administration was stopped at the end of the pPCI. The administration of saline was the same as those in the DEX group. The primary endpoint was the myocardial infarct size (MIS) as assessed by cardiac magnetic resonance imaging (CMR) at 5±2 days post-STEMI. Based on a superiority design and assuming an 20.0% relative infarct size reduction (from 26.0% to 20.8% with a SD of 13.0%), 250 patients are required to be enrolled, accounting for 20% drop-out (α= 0.05 and power= 80%).",[225,226,227],"ST-segment Elevation Myocardial Infarction (STEMI)","Percutaneous Coronary Intervention","Cardioprotection",[225,229,230,227],"Percutaneous coronary intervention","Dexmedetomidine","2024-10-11",{"date":233,"type":234},"2024-10-15","ACTUAL",{"date":236,"type":234},"2021-05-27",{"date":238,"type":219},"2025-12",{"name":5,"class":6},9]